Abeona Therapeutics Moves Forward with Pz-cel BLA Resubmission
Abeona Therapeutics Inc. today shared exciting news regarding the resubmission of its Biologics License Application (BLA) for pz-cel, an innovative autologous cell-based gene therapy, to the U.S. Food and Drug Administration (FDA). This promising treatment targets patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that severely affects skin integrity.
Collaboration with the FDA
Vish Seshadri, the CEO of Abeona, expressed gratitude towards the FDA for their continuous guidance throughout this rigorous process. "We have meticulously worked with the Agency to ensure that our resubmission package addresses all feedback provided, particularly the Chemistry Manufacturing and Controls (CMC) aspects highlighted in the earlier response letter. We are optimistic about the review process ahead of us as we seek to assist the FDA in evaluating our application," he stated.
Understanding the Resubmission Process
The latest BLA submission follows a productive Type A meeting with the FDA, where Abeona outlined the necessary adjustments to meet the CMC requirements from the Complete Response Letter received earlier. Importantly, the FDA's previous feedback did not point to any clinical data deficiencies, meaning that no additional clinical trials were mandated. The resubmission leverages data from the pivotal Phase 3 VIITAL™ study and a Phase 1/2a investigation, which underline the efficacy and safety of pz-cel.
Implications for Patients
With the BLA resubmission now off to the FDA, Abeona anticipates a new Prescription Drug User Fee Act (PDUFA) action date for pz-cel to be established. Usually, the review of a resubmitted BLA can span either two or six months, depending on the classification assigned by the FDA. A timely acceptance decision is typically made within a two-week window following the submission-related activities.
About Pz-cel and Its Development
Pz-cel represents a groundbreaking approach in the treatment of RDEB. This gene therapy utilizes the patient's own skin cells, corrected with a functional COL7A1 gene, to produce collagen VII – a crucial protein for maintaining skin integrity. Patients with RDEB suffer from inadequate anchoring fibrils, leading to fragile skin and painful wounds. Pz-cel aims to significantly alleviate these symptoms by regenerating properly functioning skin cells.
Key Features of Pz-cel
Apart from its significant therapeutic potential, pz-cel has garnered several prestigious designations from the FDA, including Regenerative Medicine Advanced Therapy, Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease status. With these recognitions, Abeona is well-positioned to expedite the development and future availability of this treatment for patients suffering from this debilitating condition.
Abeona Therapeutics' Commitment
Abeona Therapeutics Inc. is dedicated to the advancement of gene and cell therapies aimed at addressing serious diseases, especially in the realm of rare conditions with substantial unmet medical needs. The company operates a cGMP manufacturing facility where pz-cel is produced, demonstrating its capability to support the therapy through to potential commercial production post-FDA approval.
Frequently Asked Questions
What is the purpose of the pz-cel therapy?
Pz-cel is an autologous gene therapy being developed to treat recessive dystrophic epidermolysis bullosa (RDEB) by correcting the underlying genetic defect that leads to severe skin fragility.
What was required for the BLA resubmission?
Abeona Therapeutics needed to address all the Chemistry Manufacturing and Controls (CMC) items specified by the FDA in the Complete Response Letter before the reapplication could proceed.
How long will the FDA take to review the BLA resubmission?
The FDA typically reviews resubmitted BLAs within either two or six months based on the classification assigned to the submission.
What designations has pz-cel received from the FDA?
Pz-cel has received multiple designations including Regenerative Medicine Advanced Therapy, Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease, which facilitate its faster development and approval process.
What distinguishes Abeona Therapeutics in the biopharmaceutical landscape?
Abeona specializes in developing advanced cell and gene therapies with a focus on serious and rare diseases, aiming to create innovative treatments where there are few options available for patients.
